Table 1 Relationship between patients’ characteristics and KRAS mutation status in adenomyosis.
From: Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations
Characteristic | KRAS wild-type patient (N = 44) | KRAS-mutated patient (N = 26) |
|---|---|---|
Median age at operation (range), years | 42.5 (21–50) | 41 (30–58) |
Preoperative treatment, no. (%) | 25/44 (56.82) | 19/26 (73.08) |
DNG, no. (%) | 2/44 (4.55) | 11/26 (42.31) |
GnRHa, no. (%) | 23/44 (52.27) | 9/26 (34.62) |
LNG-IUS, no. (%) | 2/44 (4.55) | 1/26 (3.85) |
PR-IHC | ||
Negative, no. (%) | 7/44 (15.91) | 13/26 (50) |
Disease co-occurrence | ||
Endometriosis, no. (%) | 26/44 (59.09) | 22/26 (84.62) |
EN-OV type, no.(%) | 12/44 (27.27) | 18/26 (69.23) |
EN-DI type, no.(%) | 9/44 (20.45) | 12/26 (46.15) |
EN-PE type, no.(%) | 14/44 (31.82) | 3/26 (11.54) |
Leiomyoma, no. (%) | 28/44 (63.64) | 13/26 (50.00) |
Ovarian cancer, no. (%) | 0/44 (0.00) | 5/26 (19.23) |
Endometrial cancer, no. (%) | 0/44 (0.00) | 1/26 (3.85) |
Cervical cancer, no. (%) | 1/44 (2.27) | 0/26 (0.00) |
MRI | ||
Endometrial subtype, no. (%) | 5/44 (11.36) | 1/26 (3.85) |
Subserous subtype, no. (%) | 9/44 (20.45) | 7/26 (26.92) |
Others (diffuse), no. (%) | 28/44(63.64) | 18/26 (69.23) |
Unknown, no. (%) | 2/44 (4.55) | 0/26 (0.00) |
History | ||
Caesarean section, no. (%) | 5/44 (11.36) | 0/26 (0.00) |
Dilatation and curettage, no. (%) | 13/44 (29.55) | 7/26 (26.92) |
Vaginal delivery, no. (%) | 5/44 (11.36) | 8/26 (30.77) |
Abortion or stillborn, no. (%) | 17/44 (38.64) | 10/26 (38.46) |
Premature birth, no. (%) | 1/44 (2.27) | 2/26 (7.69) |
Hysterectomy, no. (%) | 16/44 (36.36) | 15/26 (57.69) |
Gravidity, no. (%) | 23/44 (52.27) | 14/26 (53.84) |
Smoking history, no. (%) | 8/44 (18.18) | 3/26 (11.54) |
